App-Quantinova.ai

The impact of immune thrombocytopenia (ITP) on activities of daily living: findings reported by UK patients and physicians from the ITP World Impact Survey (I‐WISh)

N. Cooper - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Immune thrombocytopenia

N/A

Prolonged corticosteroid use in newly diagnosed primary immune thrombocytopenia

K. Burton - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Immune thrombocytopenia

Mycophenolate mofetil

Patients’ and health care professionals’ perspectives on treatment goals in sickle cell disease – a UK perspective: results from the International Sickle Cell World Assessment Survey (SWAY)

B. Inusa - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Sickle cell anemia

N/A

Iron deficiency diagnosis in pregnancy using reticulocyte haemoglobin equivalent

N. Priddee - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Anemia

N/A

Prevalence of anaemia in late pregnancy ‐ a measure of whether national guidelines have been successfully implemented

R. Farnell - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Ferric carboxymaltose

Final results from the apixaban length‐of‐stay pulmonary embolism study ‐ Hospital Admissions (ALPHA‐PE)

R. Alikhan - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

Hydroxyzine

Immunological effects of ponatinib therapy in patients with chronic myeloid leukaemia

P. Harrington - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Myelogenous Leukemia

Ponatinib

When should haematologists see patients with asymptomatic lymphocytosis?

P. Johnstone - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Mucosa-associated lymphoid tissue lymphoma

N/A

UK adult immune thrombocytopenia (ITP) pregnancy registry: collaborative research to better understand outcomes: the first 18 months

P. Raheja - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Immune thrombocytopenia

IVIG

Transition to generic imatinib: a single‐centre experience of patient and financial outcomes

G. Hess - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Myelogenous Leukemia

Imatinib

Refining the erythrocytosis diagnostic pathway: an audit of current practice compared to British Society for Haematology guidelines

R. Williams - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Polycythaemia vera

Erythropoietin

A clinical audit on compliance with British Society of Haematology guidelines for diagnosis and management of Philadelphia negative myeloproliferative neoplasms

F. Karim - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Myeloid neoplasms

Hydroxycarbamide

Disease progression in patients with essential thrombocythaemia receiving anagrelide within a single institution

N. Gray - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Essential thrombocythemia

Anagrelide hydrochloride

Second primary malignancies in patients receiving treatment with ruxolitinib for myelofibrosis – a regional experience

J. Schofield - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

Ruxolitinib phosphate

Stopping IM B12: a collaborative service development between primary and secondary care

M. Griffin - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Dementia

Cyanocobalamin

Renal function over 10 years in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors: a single centre experience

R. Hinton - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Chronic Myelogenous Leukemia

Bosutinib

Low haemoglobin A1c (HbA1c) result: lessons learnt in clinical practice

M. Khalifa - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Autoimmune hemolytic anemia

Dapsone

Patients’ and physicians’ perceptions of treatments and goal setting in immune thrombocytopenia (ITP): findings reported by UK patients and physicians from the ITP World Impact Survey (I‐WISh)

N. Cooper - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Immune thrombocytopenia

N/A

Comparison of 8G and 11G trephine needle size on sample quality, sufficiency and ease of procedure

W. Wechie - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Ruxolitinib in myelofibrosis: a multicentre analysis of real‐world patients in England, Northern Ireland and Wales

J. Russell - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Myeloid neoplasms

Ruxolitinib phosphate

Filters

45280 Abstracts